+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Theravance Biopharma - logo

Theravance Biopharma is a biopharmaceutical company that develops and commercializes human therapeutics. The company offers VIBATIV (telavancin), a bactericidal, once-daily injectable antibiotic. In addition, it has numerous product candidates, including Revefenacin (TD-4208), Axelopran, Velusetrag, TD-6450 and others. It also focuses on various drug development programs, including the combination of fluticasone furoate, umeclidinium, and vilanterol. Founded in 2013, it is based in George Town, the Cayman Islands.

From
Lower Respiratory Tract Therapeutics Global Market Report 2024 - Product Thumbnail Image

Lower Respiratory Tract Therapeutics Global Market Report 2024

  • Report
  • February 2024
  • 175 Pages
  • Global
From
From
Gastroparesis Global Market Report 2024 - Product Thumbnail Image

Gastroparesis Global Market Report 2024

  • Report
  • February 2024
  • 175 Pages
  • Global
From
From
From
Constipation - Pipeline Insight, 2024 - Product Thumbnail Image

Constipation - Pipeline Insight, 2024

  • Clinical Trials
  • April 2024
  • 90 Pages
  • Global
From
From
Gastroparesis - Pipeline Insight, 2024 - Product Thumbnail Image

Gastroparesis - Pipeline Insight, 2024

  • Clinical Trials
  • April 2024
  • 50 Pages
  • Global
From
COPD: Update Bulletin - Product Thumbnail Image

COPD: Update Bulletin

  • Newsletter
  • May 2024
  • Global
From
Beta Receptor Agonist - Pipeline Insight, 2024 - Product Thumbnail Image

Beta Receptor Agonist - Pipeline Insight, 2024

  • Clinical Trials
  • January 2024
  • 120 Pages
  • Global
From
From
From
Multidrug Resistant Bacteria Global Market Report 2024 - Product Thumbnail Image

Multidrug Resistant Bacteria Global Market Report 2024

  • Report
  • January 2024
  • 175 Pages
  • Global
From
Crohn's disease - Pipeline Insight, 2024 - Product Thumbnail Image

Crohn's disease - Pipeline Insight, 2024

  • Clinical Trials
  • April 2024
  • 240 Pages
  • Global
From
Mu Antagonist - Pipeline Insight, 2024 - Product Thumbnail Image

Mu Antagonist - Pipeline Insight, 2024

  • Clinical Trials
  • January 2024
  • 60 Pages
  • Global
From
From
Loading Indicator